---
title: "Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289994304.md"
description: "Aura Biosciences CFO Anthony S. Gibney sold 12,824 shares worth $82,330 on June 16, 2026. This insider move coincides with the company completing Phase 3 trial enrollment for belzupacap sarotalocan, with topline data expected in late 2027. Despite recent corporate events like equity financing and leadership changes, TipRanks' AI analyst rates AURA as Neutral due to weak financials, including no revenue and high cash burn."
datetime: "2026-06-17T02:11:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289994304.md)
  - [en](https://longbridge.com/en/news/289994304.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289994304.md)
generator: "portal-rs"
---

# Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move

New insider activity at Aura Biosciences Inc ( (AURA) ) has taken place on June 16, 2026.

Aura Biosciences Inc’s Chief Financial and Business Officer, Anthony S. Gibney, has recently trimmed his stake in the company, selling 12,824 shares of Aura Biosciences Inc stock in a transaction valued at $82,330.

Aura Biosciences shares were influenced by news that it completed enrollment of 108 patients in its Phase 3 trial of belzupacap sarotalocan for early choroidal melanoma, with topline data expected in the second half of 2027. Analyst price target revisions referenced in prior coverage have largely been driven by earlier Q1 results, leadership changes with a new CEO, significant equity financing, and a stock repurchase agreement, which together reshape Aura’s risk, dilution, and funding profile.

**Spark’s Take on AURA Stock**

According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.

Overall score is held down primarily by weak financial performance (no revenue, widening losses, and heavy ongoing cash burn) and bearish technicals (below major moving averages with negative momentum). Offsetting factors include supportive corporate events that strengthen liquidity and extend the cash runway, while valuation inputs are not very informative due to negative earnings and no dividend.

To see Spark’s full report on AURA stock,  
 click here. 

**More about Aura Biosciences Inc**

**YTD Price Performance:** 18.35%

**Average Trading Volume:** 517,525

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $662.7M

### Related Stocks

- [AURA.US](https://longbridge.com/en/quote/AURA.US.md)

## Related News & Research

- [Aura Biosciences grants new executives stock options priced at $7.43, plus RSUs](https://longbridge.com/en/news/297695014.md)
- [Aura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 million](https://longbridge.com/en/news/295525945.md)
- [Aura Minerals executives cut stake by R$ 7.24 million after share sales](https://longbridge.com/en/news/298645902.md)
- [EAIGG and Draup Launch "The AI Sovereignty Paradox," Introducing a New Framework for Understanding National AI Competitiveness](https://longbridge.com/en/news/298428258.md)
- [Aura Minerals director Bruno Sousa Mauad disposes of USD 52,040 in common shares](https://longbridge.com/en/news/298518373.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**